• National HealthCare Corporation reported third quarter 2026 revenue of US$407.97 million versus US$382.66 million a year earlier, while net income fell to US$13.64 million from US$39.24 million and diluted EPS from continuing operations moved to US$0.85 from US$2.50.
• Across the first nine months of 2026, National HealthCare showed higher revenue than the prior year yet slightly lower net income and earnings per share. This combination suggests heavier cost pressure or shifts in business mix despite ongoing demand.
• Next, the focus will be on how National HealthCare’s weaker quarterly earnings and compressed EPS shape the broader investment narrative that investors follow.

Spot 32 resilient stocks with low risk scores for healthcare investors who want National HealthCare’s steadier profile, alongside other resilient businesses with lower risk scores.

What Is National HealthCare's Investment Narrative?

To own National HealthCare, you need to be comfortable with a fairly capital heavy care platform that depends on steady demand for skilled nursing, assisted living, and home health services. The big picture belief is that a broad mix of inpatient, hospice, and ancillary operations can support earnings over time, even when one area hits a rough patch. The latest quarter fits that trade off. Revenue moved higher while profit and EPS compressed, which points to cost pressure and possibly tighter pricing or reimbursement on parts of the portfolio.

In the short term, the key swing factors are execution on staffing and expenses in facilities, reimbursement trends across Medicare and managed care, and how management allocates cash between maintaining properties and growth. The recent earnings miss on the bottom line does not erase National HealthCare’s record of earnings growth over the past year and over the past five years, but it does make the near term cost story more important. A P/E below the broader healthcare sector suggests some investors already price in those questions. The share price pullback over the past month signals sensitivity to any hint that margins are under strain.

Even so, there is one underappreciated pressure point that could matter far more for National HealthCare if...

There's only one way to know the right time to buy, sell or hold National HealthCare. Head to Simply Wall St's company report for the latest analysis of National HealthCare's Fair Value.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community sit far apart, with one retail investor seeing National HealthCare as worth just 0.22 times the current share price and another implying a value that is very large by comparison. Those views were set before the November 5 earnings release, so you may want to revisit them in light of the latest margin pressure.

Explore another National HealthCare fair value estimate, including one that suggests up to 100% downside from the current price!

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your National HealthCare research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for National HealthCare. This report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate National HealthCare's overall financial health at a glance.

Looking For More Investment Ideas Beyond National HealthCare?

If you want to balance your view on National HealthCare with a broader watchlist, the Simply Wall St Screener can help you line up other candidates that fit different risk and income profiles.

• For income seekers who care about consistency as much as yield, check out 6 dividend fortresses that may help anchor a portfolio with regular cash returns.
• If capital preservation sits at the top of your priority list, scan through the 32 resilient stocks with low risk scores to compare National HealthCare with companies that score lower on risk.
• When you want to broaden the opportunity set beyond well known tickers, use the 21 high quality undiscovered gems that might otherwise sit off most investors' radar.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.